SCIENCE

IgE-related allergic diseases such as atopic dermatitis, allergic asthma, hyper-IgE syndrome, and food allergies

Treats and prevents allergic diseases by inhibiting the B lymphocytes, which express mIgE

1. Completed a phase I clinical trial in the US
2. Completed a phase IIa clinical trial of atopic dermatitis in the US
3. A phase IIa clinical trial in allergic asthma in Taiwan is ongoing
4. A phase II clinical trial of the subcutaneous injection formulation for moderate to severe atopic dermatitis in Taiwan and the United States is ongoing

1. Uniqueness: Has a novel drug target and mechanism by inhibiting the source of IgE, i.e., the mIgE B cells.
2. Safety: Has a specific pharmacological mechanism and limited side effects.
3. Extensive use: Has a wide range of indications and applies to more allergy and asthma patients than its existing counterparts.
4. Economy: FB825 has excellent pharmacokinetic properties and a long half-life. It is anticipated to be administered once every 2-3 months. The long-acting advantage provides great convenience to patients and helps reduce medical costs.

According to analysis reports by Allied Market Research and Coherent Market Insights, the global market size of atopic dermatitis/asthma treatment will reach USD 38 billion in 2027.